A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
- Sponsor
- Lymphoma Study Association
- Study ID
- NCT00169156
- Phase
- PHASE2
- Status
- Completed
Conditions
- Untreated T-cell Angioimmunoblastic Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG375 mg/m2 D1
- Prednisone — DRUG40 mg/m2 D1 to D5
- Doxorubicine — DRUG50 mg/m2 D1
- Cyclophosphamide — DRUG750 mg/m2 D1
- Vincristine — DRUG1,4 mg/m2 D1
Study Details
To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and rituximab in patients aged 60 to 80 years with previously untreated AIL.
Key Dates
- Start date
- Dec 31, 2005
- Status verified
- Mar 2017
- Primary completion
- Dec 31, 2008
- Completion
- Nov 30, 2012
Study Design
- Enrollment
- 27 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Rituximab + CHOPRituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
Primary Outcome Measure
Overall Response Rate (ORR) [ Time Frame: 8 months (4 cycles of treatment + 4 cycles of consolidation) ]